Siramesine

DB06555ExperimentalSmall molecule

Investigated for use/treatment in anxiety disorders.

Chemical structure of Siramesine
Primary indication
Investigated for use/treatment in anxiety disorders.Curator reviewed
Formula / weight
C30H31FN2O · 454.589 g/mol (avg)

Resolves to

Compound
UNII3IX8CWR24VCAS147817-50-3ChEMBLCHEMBL61479
Structure
InChIKeyXWAONOGAGZNUSF-UHFFFAOYSA-NSMILESFC1=CC=C(C=C1)N1C=C(CCCCN2CCC3(CC2)OCC2=CC=CC=C32)C2=CC=CC=C12
Targets
P35368ADRA1BP25100ADRA1DP35348ADRA1A

What you can answer from here — as of March 06, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Siramesine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In